Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Pieris Pharmaceuticals Inc
PIRS
Healthcare
Biotechnology
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4...
-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PIRS)
New Post
View:
Posts & Comments
Threaded Posts
(227)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 24, 2024 10:02am
Palvella Therapeutics and Pieris Pharmaceuticals Announce De
Breaking News: $PIRS Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger AgreementProposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on
...more
(59)
•••
Nibinator
X
View Profile
View Bullboard History
Post by
Nibinator
on May 04, 2024 10:33pm
BUY BUY BUY BUY BUY
Before it erupt
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(4)
•••
AviseAnalytics
X
View Profile
View Bullboard History
Post by
AviseAnalytics
on Oct 11, 2021 7:46am
PIERIS’S ANTICALIN COULD BE A GAMECHANGER!
$PIRS Pieris Pharmaceuticals, (NASDAQ: PIRS) is a clinical-stage biopharmaceutical company that is leveraging its proprietary Anticalin® technology for creating novel therapeutics for the
...more
(37)
•••
RetailInvestor9
X
View Profile
View Bullboard History
Post by
RetailInvestor9
on May 25, 2021 7:09pm
Anybody home??
Looks like no one was talking about this stock until today. Well let's get a conversation started... anyone who made their pay day swing trading this stock today??
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden